Group 1 - Beyond Air Inc (NASDAQ:XAIR) is recognized as a promising penny stock, with analysts highlighting its potential in the market [1] - A recent peer-reviewed article emphasized the efficacy of high-dose inhaled nitric oxide as a therapy for respiratory illnesses, summarizing data from 27 studies [2] - The article also identified therapeutic opportunities for inhaled nitric oxide in conditions such as hospital-acquired pneumonia, tuberculosis, and post-viral fibrosis [2] Group 2 - Beyond Air has developed a nitric oxide generator and delivery platform named LungFit, with sales from its LungFit PH system increasing by 105% year-over-year to $2.2 million in the December quarter [3] - The LungFit PH system is specifically designed for treating term and near-term neonates suffering from hypoxic respiratory failure [3] - Beyond Air Inc is headquartered in Garden City, New York, and focuses on using nitric oxide for treating respiratory diseases and other medical conditions [4]